<DOC>
	<DOCNO>NCT01706692</DOCNO>
	<brief_summary>The purpose study evaluate long-term course patient psoriasis psoriatic-arthritis systemic treatment , methotrexate , cyclosporin A , fumaric acid , acitretin , systemic PUVA , etanercept , infliximab , adalimumab ustekinumab . A patient include first initiation treatment remain registry 5 year , regardless subsequent therapy . The registry also evaluate safety clinical outcome health relate quality life .</brief_summary>
	<brief_title>Swiss Dermatology Network Targeted Therapies ( SDNTT )</brief_title>
	<detailed_description>Treatment moderate severe Psoriasis ( Pso ) Psoriasis-Arthritis ( PsA ) Switzerland largely perform systemic therapy . This include conventional systemic therapy fumaric acid , methotrexate , cyclosporin A , retinoids , systemic PUVA , Acitretin biological treatment etanercept , infliximab , adalimumab within pre-registration program ustekinumab . While short- middle-term efficacy systemic treatment show clinical study ( incorporated international guideline ) , knowledge long-term outcome , optimal treatment effectiveness real-world condition still miss . SDNTT , Swiss registry treatment moderate severe Pso PsA document long-term course patient administer defined biologic conventional systemic drug . Following outcomes observe : Effectiveness long-term , combined/alternating treatment comorbidity condition ; patient-defined benefit quality life , maintenance dosage , prediction response safety . The study evaluate long-term course patient Pso PsA systemic treatment . A patient include first initiation treatment remain registry 5 year , regardless subsequent therapy . Nationwide , initially 35 ( long-term approx . 50-80 ) dermatologic practice hospital ambulance expertise systemic biologic treatment consecutively enroll patient . Follow-ups every 3 month , comprise patient treatment characteristic , clinical parameter , patient-defined benefit , quality life adverse event . Standardized questionnaire address patient dermatologist 12 time dermatologic centre . In interim interval , patient directly contact another 9 time mail .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients diagnosis plaquetype psoriasis psoriasis arthritis confirm dermatologist , age â‰¥ 18 , Being administer specific biologic/conventional systemic drug first time Sufficient language skill ( German , French , Italian English ) inform consent participate Informed consent participate Lack informed consent Patients participant clinical trial day registration registry ( patient include clinical trial registry followup , patient data record , analyze separately )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Methotrexate</keyword>
	<keyword>Acitretin</keyword>
	<keyword>Cyclosporine A</keyword>
	<keyword>Systemic PUVA</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Etanercept</keyword>
	<keyword>Ustekinumab</keyword>
	<keyword>Fumaric acid</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Psoriatic arthritis</keyword>
	<keyword>Skin disease</keyword>
</DOC>